12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tivantinib: SPA received

ArQule said it reached an agreement with FDA on an SPA for a double-blind, international Phase III trial to evaluate tivantinib in about 300 previously treated patients with high inoperable HCC that is positive for c-Met based on a diagnostic. ArQule is co-developing tivantinib with Daiichi Sankyo on a worldwide basis outside of certain Asian countries, where ArQule licensed rights to...

Read the full 282 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >